• linkedin
  • Increase Font
  • Sharebar

    2017’s big breakthroughs

    The dermatology community experienced big strides in medical and cosmetic dermatology in 2017. Dermatologists share what they think were major breakthroughs throughout the year.

    A new, in-office seborrheic keratosis treatment

    In December 2017, Aclaris Therapeutics announced FDA approval for ESKATA (A-101) for the treatment of raised seborrheic keratoses (SKs).

    It’s exciting to have a new option, which can be applied in the office, for patients with these frustrating, annoying lesions, according to dermatologist Rhonda Klein, M.D., M.P.H.

    Dr. Klein“A-101 is a proprietary high-concentration 40% hydrogen-peroxide based topical solution for seborrheic keratoses, a very common skin lesion affecting more than 83 million Americans,” says Dr. Klein, who practices with Connecticut Dermatology Group and has no financial or research ties to ESKATA.

    Dermatologists apply the treatment directly on the raised SK, using a pen-like applicator.

    The FDA’s approval of ESKATA is based on two pivotal Phase 3 trials, in which patients received up to two treatments with ESKATA—one at the start of therapy and a second at week three. Treatment with ESKATA was generally well-tolerated and was more likely to result in complete SK clearing, compared to placebo, according to a company press release.

    “It is also being studied for verruca vulgaris (warts) at a higher concentration,” Dr. Klein says.

    Conflicts of interest for Dr. Klein: none.

    NEXT: Siliq


    Lisette Hilton
    Lisette Hilton, president of Words Come Alive, has written about health care, the science and business of medicine, fitness and wellness ...


    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available

    Latest Tweets Follow